Dynavax Technologies | DVAX - Assets


Dynavax Technologies reported $946.51M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
AbbVie USD 133.9B 3.28B Sep/2025
Adma Biologics USD 568.69M 10.31M Sep/2025
Amgen USD 90.14B 2.24B Sep/2025
AstraZeneca USD 114.46B 2.03B Sep/2025
Biogen USD 29.21B 877.3M Sep/2025
BioMarin Pharmaceutical USD 7.61B 158.53M Sep/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Dynavax Technologies USD 946.51M 28.06M Sep/2025
Gilead Sciences USD 58.53B 2.81B Sep/2025
Glaxosmithkline GBP 82.45B 23.19B Sep/2025
Merck USD 129.55B 12.02B Sep/2025
Neurocrine Biosciences USD 4.27B 375.9M Sep/2025
Novartis USD 107.29B 2.89B Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sarepta Therapeutics USD 3.49B 186.38M Sep/2025
TG Therapeutics USD 1.03B 322.41M Sep/2025
Vertex Pharmaceuticals USD 24.86B 825.6M Sep/2025